PRPierre Ronco

Pierre Ronco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pierre Ronco has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Flyscan opportunities in medicine: the case of quantum rattle based on gold quantum dots

    by Emmanuel Esteve, Solenn Reguer, Cédric Boissiere, Corinne Chanéac, Gustavo Lugo, Chantal Jouanneau, Cristian Mocuta, Dominique Thiaudière, Nicolas Leclercq, Bernard Leyh, et al.

    The new rapid scan method, Flyscan mode, implemented on the DiffAbs beamline at Synchrotron SOLEIL, allows fast micro-X-ray fluorescence data acquisition. It paves the way for applications in the biomedical field where a large amount of data is needed to generate meaningful information for the clinician. This study presents a complete set of data acquired after injection of gold-cluster-enriched mesoporous silica nanospheres, used as potential theranostic vectors, into rats. While classical X-ray fluorescence investigations (using step-by-step acquisitions) are based on a limited number of samples (approximately one per day at the DiffAbs beamline), the Flyscan mode has enabled gathering information on the interaction of nanometer-scale vectors in different organs such as liver, spleen and kidney at the micrometer scale, for five rats, in only a single five-day synchrotron shift. Moreover, numerous X-ray absorption near-edge structure spectra, which are beam-time-consuming taking into account the low concentration of these theranostic vectors, were collected.


  • Col4a1 mutation generates vascular abnormalities correlated with neuronal damage in a mouse model of HANAC syndrome

    by Alix Trouillet, Henri Lorach, Elisabeth Dubus, Brahim El Mathari, Ivana Ivkovic, Julie Dégardin, Manuel Simonutti, Michel Paques, Xavier Guillonneau, Florian Sennlaub, et al.


    • 1 February 2016
      • p. 33.S66.7

    Gabriel Richet: the Man and the Scientist.

    by Raymond Ardaillou, Pierre Ronco

    Gabriel Richet who died in Paris in October 2014 was the fourth of a brilliant dynasty of professors of medicine including a Nobel prize, his grandfather, Charles Richet. He behaved courageously during the Second World War and participated in the Campaign of France in 1940 and in the combats in the Vosges Mountains in 1945. His family participated in the resistance during the German occupation of France and three of his parents including his father, one of his brothers and one of his cousins were deported in Germany. At the end of the war, he was with Jean Hamburger the founder of French nephrology at Necker Hospital in Paris. He realized the first hemodialyses in France and was involved in the first allogenic transplantation that was not immediately rejected. From 1961 to 1985, he was the head of a school of nephrology at Tenon Hospital and attracted in his department many young collaborators and scientists. He was the first to describe the role of specialized cells of the collecting duct in the control of acid base equilibrium. He was the subject of a national and international recognition. Founding member of the International Society of Nephrology in 1960, he was elected his President from 1981-1984. His fame could be measured by the number of fellows and visiting facultiesfrom countries all over the world. When he retired in 1985, he left an important legacy involving several departments of nephrology directed by his ancient collaborators. After his retirement, he was an active member of the French Academy of Medicine and devoted much of his time to the history of medicine and, particularly, of nephrology. The main qualities of the man were his constant research of new ideas, his eagerness to work and his open mind to understand others.

  • Open Access

    Allo-Immune Membranous Nephropathy and Recombinant Aryl Sulfatase Replacement Therapy

    by Hanna Debiec, Vassili Valayannopoulos, Olivia Boyer, Laure-Hélène Nöel, Patrice Callard, Hélène Sarda, Pascale de Lonlay, Patrick Niaudet, Pierre Ronco

    Nephrotic syndrome was reported in a highly-sensitized patient receiving enzyme replacement therapy (ERT) for Pompe disease, but the prevalence of ERT-induced renal complications and mechanisms to facilitate readministration of ERT in these patients remain unexplored. This work identifies a new antigen responsible for secondary membranous nephropathy (MN) in a patient with mucopolysaccharidosis type VI caused by aryl sulfatase B (ASB) deficiency. ERT (recombinant human ASB [rhASB]; 1 mg/kg per week) started at the age of 4 years led to a high anti-rhASB titer and dramatically improved clinical manifestations. However, 16 months later, the patient suddenly developed nephrotic syndrome resistant to steroid therapy 1 week after orthopedic surgery. Examination of the kidney biopsy specimen revealed glomerular deposition of IgG (mostly IgG4, C3, and C5b-9) in a granular pattern typical of MN. Double immunofluorescence staining showed that subepithelial granular deposits contained rhASB colocalized with IgG. Ig eluted from the patient’s biopsy specimen reacted specifically with rhASB. On discontinuation of ERT, proteinuria progressively decreased, but the patient's clinical condition markedly deteriorated. Induction of tolerance to rhASB was initiated by coadministration of low-dose corticosteroids, rituximab, intravenous Igs, and oral methotrexate. ERT was resumed 8 weeks after starting immunosuppressive therapy without inducing a rebound of antibody titer or an increase in proteinuria. We conclude that the allo-immune response to the recombinant rhASB caused the nephropathy. Considering the critical requirement for ERT in patients with such enzyme deficiencies, immune tolerance induction should be advocated in the patients with allo-immune MN.


  • Open Access

    Renal arterial resistive index is associated with severe histological changes and poor renal outcome during chronic kidney disease

    by Naïke Bigé, Pierre Patrick Lévy, Patrice Callard, Jean-Manuel Faintuch, Valérie Chigot, Virginie Jousselin, Pierre Ronco, Jean-Jacques Boffa

    Chronic kidney disease (CKD) is a growing public health problem and end stage renal disease (ESRD) represents a large human and economic burden. It is important to identify patients at high risk of ESRD. In order to determine whether renal Doppler resistive index (RI) may discriminate those patients, we analyzed whether RI was associated with identified prognosis factors of CKD, in particular histological findings, and with renal outcome.


  • Non-Randall Glomerulonephritis with Non-organized Monoclonal Ig Deposits

    by Pierre Ronco, Alexandre Karras, Emmanuelle Plaisier

    • 1 January 2012
      • Vol. 62  (1) , 72-5

    [Chronic kidney disease, new therapeutic approaches].

    by Jean-Jacques Boffa, Jean-Claude Dussaule, Pierre Ronco, Christos Chatziantoniou

    Despite the use of angiotensin blockers, chronic kidney diseases still progress. New therapeutic approaches aim to strengthen and to complete angiotensin blocker effects. Endothelin receptor antagonists, in addition to angiotensin blockers reduce blood pressure and urinary albumin excretion in diabetic nephropathies but can induce fluid overload. A second therapeutic approach consists in preventing the development of interstitial renal fibrosis which is a prognostic factor of CKD. Transforming growth factor-beta (TGF-beta) plays a major role in this process. Several molecules such as pirfenidone, microARN are in development to block TGF-beta or its downstream signaling pathways. Another approach aims to promote resolution of inflammation and renal repair Interesting experimental results were obtained with tyrosine kinase inhibitors and with methyl of bardoxolone in humans.


  • Advances in membranous nephropathy: Success stories of a long journey

    by Pierre Ronco, Hanna Debiec

    Summary: 1. embranous nephropathy is characterized by an accumulation of immune deposits on the outer aspect of the glomerular basement membrane.2. In the rat model described by Heymann in 1959, the target antigen of antibodies is megalin, a multiligand receptor expressed in the rat glomerulus but absent from the human glomerulus.3. In recent years, two major antigens have been identified in human membranous nephropathy (MN). The first is neutral endopeptidase (NEP), the alloantigen involved in neonatal cases of MN that occur in newborns from NEP‐deficient mothers. The second is the M‐type phospholipase A2 receptor (PLA2R), the first autoantigen identified in idiopathic MN in the adult. Megalin, NEP and PLA2R are all expressed on the podocyte surface, where they can serve as targets for circulating antibodies, leading to in situ immune complex formation, complement activation and proteinuria.4. In addition to podocyte antigens, we recently showed that some patients with childhood MN had both circulating cationic bovine serum albumin (BSA) and anti‐BSA antibodies, with BSA being present in immune deposits. This suggests that food antigens may be involved in MN through charge‐dependent binding to the anionic glomerular capillary wall and in situ formation of immune complexes.